Is this U.S.-China selloff a buy? A top Wall Street voice weighs in
Investing.com - Cantor Fitzgerald maintained its Overweight rating and $678.00 price target on Regeneron Pharmaceuticals (NASDAQ:REGN), a $58.5 billion market cap biotechnology company, following its third-quarter financial results. According to InvestingPro analysis, the stock is currently trading below its Fair Value, suggesting potential upside opportunity.
The investment firm described Regeneron’s quarterly performance as "largely in-line" with expectations, suggesting the financial results met analyst projections without significant deviation. The company maintains strong financial health, with InvestingPro data showing a healthy current ratio of 4.6 and moderate debt levels.
Cantor Fitzgerald noted that investor attention will likely shift from these quarterly results to the upcoming pre-filled syringe PDUFA date scheduled for late October, which represents a key regulatory milestone for the company.
With Regeneron shares trading in the $570s, the firm expressed a positive outlook regarding the upcoming regulatory decision, indicating it sees "a bias towards another 90-day push or approval versus CRL [Complete Response Letter]."
The analyst acknowledged this view "may appear overly optimistic" given Regeneron’s use of a back-up fill/finish site for its Libtayo adjusted CSCC sBLA, referring to a previous supplemental Biologics License Application for the company’s cancer treatment.
In other recent news, Regeneron Pharmaceuticals received FDA approval for its drug Libtayo as an adjuvant treatment for adults with cutaneous squamous cell carcinoma (CSCC) at high risk of recurrence after surgery and radiation. The approval was based on the Phase 3 C-POST trial, which showed a 68% reduction in disease recurrence or death compared to placebo. In related developments, RBC Capital raised its price target for Regeneron to $704, citing expected growth in sales of the company’s Dupixent drug. Regeneron also announced it anticipates an $83 million acquired in-process research and development (IPR&D) charge in its third quarter 2025 results, primarily due to a payment to Hansoh Pharmaceuticals as part of a license agreement. Additionally, Regeneron reached a settlement with Formycon and Valorum, allowing the launch of Formycon’s Eylea biosimilar in the U.S. by the fourth quarter of 2026. These developments reflect significant regulatory, financial, and strategic activities for Regeneron.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.